Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 22, 2011

Clinigene and Spaulding Clinical Forge Pact for Clinical Trial Management

  • India-based Clinigene and U.S. firm Spaulding Clinical Research are joining forces to offer clinical pharmacology services. Clinigene has a central and bioanalytical laboratory as well as Phase I–IV clinical research facilities. Spaulding Clinical Research has expertise in clinical pharmacology, has a cardiac core lab, and is a medical device manufacturer. 

    "The strengths of both companies are very complementary with Clinigene providing the preclinical development (through sister company Syngene), Spaulding providing FIH/SAD/MAD, and Clinigene providing drug-drug interactions and efficient proof-of-concept, supported by Clinigene's central and bioanalytical laboratories,” remarks Abhijit Barve, COO of Clinigene. 

    Randol Spaulding, CEO of Spaulding Clinical, adds, “With Clinigene's expertise and cost-effective approach to bioavailability/bioequivalence and Spaulding's market-leading TQT study and cardiac core lab expertise, our clients are able to easily structure a program for their compound that delivers high value while keeping the molecule knowledge experts involved throughout the entire early clinical development of the compound."

    Clinigene operates a CAP-accredited central laboratory and GLP-compliant bioanalytical laboratory for small and large molecules as well as a 94-bed clinical pharmacology unit in Bangalore. Spaulding Clinical operates a 105-bed clinical pharmacology unit with 96 beds of Mortara telemetry in West Bend, WI. The facility is paperless with a Phase I electronic data capture system and bi-directional interfaces to safety lab, bedside devices and telemetry. 

    As a Phase I–IV cardiac core laboratory provider, Spaulding offers the complete suite of equipment provisioning and electrocardiogram over-reading services. This includes the Spaulding iQ Electrocardiograph. Both partners have a data solution teams to support clients study data requirements.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »